dies may further provide novel insights into their role in glioma progressionDysregulated metabolic pathways have been appreciated to be intimately associated with tumorigenesis and patient prognosis Here, we sought to develop a novel prognostic signature based on metabolic pathways in patients with primary oral squamous cell carcinoma OSCC The original RNA-seq data of OSCC from The Cancer Genome Atlas TCGA project and Gene Expression Omnibus GEO database were transformed into a metabolic pathway enrichment score matrix by single-sample gene set enrichment analysis ssGSEA A novel prognostic signature based on metabolic pathways was constructed by LASSO and stepwise Cox regression analysis in the training cohort and validated in both testing and validation cohorts The optimal cut-off value was obtained using the Youden index by receiver operating characteristic ROC curve The overall survival curves were plotted by the Kaplan-Meier method A time-dependent ROC curve analysis with 1, 3, 5 years as the defining point was performed to evaluate the predictive value of this prognostic signature A 5-metabolic pathways prognostic signature 5MPS for OSCC was constructed which stratified patients into subgroups with favorable or inferior survival It served as an independent prognostic factor for patient survival and had a satisfactory predictive performance for OSCC Our results developed a novel prognostic signature based on dysregulated metabolic pathways in OSCC and provided support for aberrant metabolism underlying OSCC tumorigenesis
  This study aimed to evaluate the prognostic role of AR-V7 in terms of prostate-specific antigen PSA response, progression-free survival PFS, and overall survival OS in CRPC patients treated with novel hormonal therapy NHT Abiraterone and Enzalutamide or taxane-based chemotherapy Docetaxel and Cabazitaxel
 
  A comprehensive literature search was conducted on PubMed, Embase, and the Web of Science from inception to February 2020 Studies focusing on the prognostic values of AR-V7 in CRPC patients treated with NHT or chemotherapy were included in our meta-analysis The OS and PFS were analyzed based on Hazard ratios HRs and 95 confidence intervals CIs Furthermore, Odds ratios ORs and 95 CIs were summarized for the AR-V7 conversion after treatment and the PSA response
 
  The AR-V7 positive proportion increased significantly after NHT treatment OR 256, 95 CI 151-432, Plt;0001, however, it declined after chemotherapy OR 051, 95 CI 028-093, P=0003 AR-V7-positive patients showedmotherapy
  Single extracranial metastases from ovarian and uterine malignancies have historically been treated with surgery or conventional radiation We report mature local control LC, overall survival OS, progression free survival PFS, and toxicity for patients who completed 5-fraction stereotactic body radiation therapy SBRT
 
  Patients with biopsy-proven, single extracranial metastases from primary ovarian and uterine malignancies treated with 5-fraction SBRT were included Patients were stratified based on tumor volume small lt; 50 cc or large ≥ 50 cc and dose low dose lt; 35 Gy or high ≥ 35 Gy Kaplan-Meier method was used to estimate LC, OS, and PFS
 
  Between July 2007 and July 2012, 20 patients underwent SBRT to a single extracranial metastasis Primary site was divided evenly between ovarian and uterine n = 10 each Metastases involved the liver 30, abdominal lymph nodes 25, lung 20, pelvic lymph nodes 10, spine 10, and extremity 5 The median gross tumor volume GTV was 42 study completion and considered cured However, patients with larger metastases ≥50 cc may require higher SBRT dosing or alternative treatments
 SBRT is a versatile, well-tolerated, and effective treatment option for single extracranial metastases from ovarian and uterine primary tumors 35 Gy in five fractions appears to be a practical minimum effective dose Four patients with small metastases were disease free at the study completion and considered cured However, patients with larger metastases ≥50 cc may require higher SBRT dosing or alternative treatmentsPituitary adenomas PAs are a neoplastic proliferation of anterior pituitary Signature of Notch pathway relies upon the histopathological type of PAs The details of Notch pathway that are involved in the migration and invasion of Pas are still unclear This paper filters and testifies the relation between Notch signaling pathway and the migration/invasion in subtypes of PAs The diversity of genes and pathways is investigated based on transcriptome data of 60 patients by KEGG pathway analysis and GSEA A series of functional experiments demonstrate the role of candidate genes by overexpression and antibody blocking in GH3 cell line Volcano map and GSEA results exhibit the differential and the priority of Jagged1 canonical Notch Ligand JAG1 in the Notch pathway combined with clinical features JAG1 is involved in epithelial-mesenchymal transition EMT in PAs by correlation analysis of RNA-seq data Progression-free survival PFS of patients with high JAG1 was shorter than patients with low JAG1 according to follow-up data P = 0006 Furthermore, overexpression and antibody blocking experiments in GH3 cell line indicate that JAG1 could promote cell proliferation, migration, and G1/S transition Double luciferase reporter assay gives manifests that JAG1 is the target gene of miR-424-3p, and mimics or inhibitor of miR-424-3p can regulate the level of JAG1 which, in turn, affects cell proliferation and the levels of MMP2 and VIM in GH3 cell line, respectively Our study delves into the relation between the Notch signaling pathway and cell proliferation and EMT in PAs, providing a potential treatment through targeting JAG1Emerging molecular diagnostic methods are more sensitive and objective, which can overcome the intrinsic failings of morphological diagnosis Here, a RT-PCR-based in vitro diagnostic test kit LungMe® was developed and characterized to simultaneously quantify the DNA methylation of SHOX2 and RASSF1A in FFPE tissue specimens The clinical manifestations were evaluated in 251 FFPE samples with specificity and sensitivity of 904 and 898, respectively Furthermore, the quantitative analysis shows that the degree of SHOX2 methylation was correlated with the stages of lung cancer, but not in the case of RASSF1A Our observation indicated that the DNA methylation of SHOX2 and RASSF1A may play different roles in cancer development Comparison of the methylation levels of SHOX2 and RASSF1A between cancer and cancer-adjacent specimens n = 30, showed they have "epigenetic field defect"  https//wwwselleckchemcom/products/salubrinalhtml  As additional clinical validation, the hypermethylation of SHOX2 and RASSF1A was detected not only in surgical operative specimens, but also in histopathological negative puncture biopsies